ARCHIVES

ODAC Recommendation for Pertuzumab Signals FDA’s Resolve In Granting Accelerated Approvals

This article is from The Cancer Letter archive.

Vol. 39 No. 35 | September 20, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Data Availability From Cancer Survey Presents Problems – Who Gets It first, Confidentiality

August 30, 1974

AACR Statement on Precancers Plays Key Role in NCI Agenda

May 30, 2003

Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer

February 25, 2011

In Brief; NCAB To Hear Report On Human Cancer Virus, Mayo Projects, Proposed FDA Regulations

February 28, 1975

Study of Dlurectic Use As Renal Cell Cancer Risk Gets Concept Approval

March 10, 1989

Cooperative Groups, NCI To Talk About Overlaps

March 14, 1975